{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:35:12Z","timestamp":1787841312998,"version":"build-2784847793"},"reference-count":8,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,1]]},"abstract":"<jats:sec>\n                    <jats:title>BACKGROUND:<\/jats:title>\n                    <jats:p>The aim of this study was to establish characteristics of lung cancer patients diagnosed at a tertiary care hospital in Bangalore.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS:<\/jats:title>\n                    <jats:p>The retrospective study was undertaken comprising of 202 patients diagnosed of advanced lung cancer in a tertiary care setting. Data was analyzed to identify patients' characteristics, smoking history, tumor histology, stage of the disease, treatment received, and survival rates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>Among the 202 patients diagnosed, 134 were males, and 68 were females. Tumor histology testing revealed that 168 patients had adenocarcinoma, 24 patients had squamous carcinoma, 5 patients had small cell carcinoma, and 5 patients were poorly differentiated carcinoma. Among the patients of adenocarcinoma, complete response, partial response (PR), stable disease, and progressive disease (PD) were seen in 0.6%, 52%, 17%, and 23.2% of the patients respectively. The median progression-free survival (PFS) for first-line treatment was 6.5 months; the highest PFS was seen with nab-paclitaxel\/platinum combination. The mean overall survival was 11.7 months and the highest OS of 12.3 months with gefitinib therapy. In the squamous subset of patients, PR was observed in fourteen patients, of which five patients were treated with nab-paclitaxel\/platinum. The mean overall survival of 10.5 months and mean PFS was 6.2 months with the highest PFS of 6.8 months were seen with weekly nab-paclitaxel. Among the small cell lung cancer patients, nine were treated with etoposide\/platinum regimen with a compliance of 6 cycles. Three patients had a PR, and one had a PD on etoposide\/platinum regimen. The mean overall survival in these patients was 4.6 months.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/0019-509x.219606","type":"journal-article","created":{"date-parts":[[2017,12,21]],"date-time":"2017-12-21T00:43:22Z","timestamp":1513817002000},"page":"276-279","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Outcomes in lung cancer: An experience from routine tertiary care setting"],"prefix":"10.4103","volume":"54","author":[{"given":"R","family":"Thippeswamy","sequence":"first","affiliation":[{"name":"Consultant Oncologist, Shankara Cancer Hospital, Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Patil","sequence":"additional","affiliation":[{"name":"Consultant, HCG Hospital, Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Prashanth","sequence":"additional","affiliation":[{"name":"Clinical Pharmacologist, Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CT","family":"Sateesh","sequence":"additional","affiliation":[{"name":"Consultant, HCG Hospital, Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Vittal","sequence":"additional","affiliation":[{"name":"Consultant Oncologist, Shankara Cancer Hospital, Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HP","family":"Shashidhara","sequence":"additional","affiliation":[{"name":"Consultant, HCG Hospital, Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KM","family":"Haridas","sequence":"additional","affiliation":[{"name":"Clinical Pharmacologist, Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2017,12,1]]},"reference":[{"key":"R1-20250920","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1200\/JCO.2011.40.4905","article-title":"Carboplatin-or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: The COCIS meta-analysis of individual patient data","volume":"30","author":"Rossi","year":"2012","journal-title":"J Clin Oncol"},{"key":"R2-20250920","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1093\/jnci\/djk196","article-title":"Cisplatin-versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: An individual patient data meta-analysis","volume":"99","author":"Ardizzoni","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"R3-20250920","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1001\/jama.292.4.470","article-title":"Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: A meta-analysis","volume":"292","author":"Delbaldo","year":"2004","journal-title":"JAMA"},{"issue":"9699","key":"R4-20250920","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/S0140-6736(09)61497-5","article-title":"Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: A randomised, double-blind, phase 3 study","volume":"374","author":"Ciuleanu","year":"2009","journal-title":"Lancet"},{"issue":"12","key":"R5-20250920","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1097\/JTO.0b013e3181c06980","article-title":"The role of histology with common first-line regimens for advanced non-small cell lung cancer: A brief report of the retrospective analysis of a three-arm randomized trial","volume":"4","author":"Scagliotti","year":"2009","journal-title":"J Thorac Oncol"},{"key":"R6-20250920","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1586\/era.10.63","article-title":"A major step towards individualized therapy of lung cancer with gefitinib: The IPASS trial and beyond","volume":"10","author":"Reck","year":"2010","journal-title":"Expert Rev Anticancer Ther"},{"issue":"Suppl","key":"R7-20250920","doi-asserted-by":"crossref","first-page":"7522","DOI":"10.1200\/jco.2012.30.15_suppl.7522","article-title":"EGFR compound mutants and survival on erlotinib in non-small cell lung cancer (NSCLC) patients (p) in the EURTAC study","volume":"30","author":"Rosell","year":"2012","journal-title":"J Clin Oncol"},{"key":"R8-20250920","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N Engl J Med"}],"container-title":["Indian Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/02223310-201754010-00056","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:49:33Z","timestamp":1787838573000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/02223310-201754010-00056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":8,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.4103\/0019-509x.219606","relation":{},"ISSN":["0019-509X","1998-4774"],"issn-type":[{"value":"0019-509X","type":"print"},{"value":"1998-4774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1]]}}}